Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

1061 results about "Subcutaneous tissue" patented technology

The subcutaneous tissue (from Latin subcutaneous, meaning 'beneath the skin'), also called the hypodermis, hypoderm (from Greek, meaning 'beneath the skin'), subcutis, or superficial fascia, is the lowermost layer of the integumentary system in vertebrates. The types of cells found in the hypodermis are fibroblasts, adipose cells, and macrophages. The hypodermis is derived from the mesoderm, but unlike the dermis, it is not derived from the dermatome region of the mesoderm. In arthropods, the hypodermis is an epidermal layer of cells that secretes the chitinous cuticle. The term also refers to a layer of cells lying immediately below the epidermis of plants.

Implantable medical electrical stimulation lead fixation method and apparatus

An implantable medical electrical lead particularly for stimulation of the sacral nerves comprises a lead body extending between a distal end and a proximal end, and the distal end having at least one electrode of an electrode array extending longitudinally from the distal end toward the proximal end. The lead body at its proximal end may be coupled to a pulse generator, additional intermediate wiring, or other stimulation device. A fixation mechanism is formed on or integrally with the lead body proximal to the electrode array that is adapted to be implanted in and engage subcutaneous tissue, particularly muscle tissue, to inhibit axial movement of the lead body and dislodgement of the stimulation electrodes. The fixation mechanism comprises a M tine elements arrayed in a tine element array along a segment of the lead proximal to the stimulation electrode array. Each tine element comprises at least N flexible, pliant, tines, each tine having a tine width and thickness and extending through a tine length from an attached tine end to a free tine end. The attached tine end is attached to the lead body from a tine attachment site and supports the tine extending outwardly of the lead body and proximally toward the lead proximal end. The M×N tines are adapted to be folded inward against the lead body when fitted into and constrained by the lumen of an introducer such that the tine free ends of more distal tines of more distal tine elements are urged toward or alongside the attached tine ends of the adjacent more proximal tines of more proximal tine elements, and the folded tines do not overlap one another.
Owner:MEDTRONIC INC +1

Injection device

An injection device for a syringe, having a syringe body, a cannula with a needle, a plunger with a plunger rod, and an injection carriage for displacing the syringe body and the plunger, comprises at least one actuating element that acts on the injection carriage to carry out the injection procedure. The actuating element (120, 220, 320) cooperates with components which withdraw the needle (108, 208, 308) from the puncture site once the injection procedure has been completed, using a return stroke (H3) that is applied to the injection carriage. A single, targeted linear movement inserts the needle to a defined depth, injects the medicament and, once the injection has been completed, produces a return stroke which allows the needle to be withdrawn into the housing and thus out from the puncture site.
The injection device is advantageously equipped with additional components which produce a delay (TV) between the completion of the injection stroke (H2) and the start of the return stroke (H3). The advantage of said delay is that the pressure that has been produced in the subcutaneous tissue by the injection of the medicament can subside before the needle is withdrawn, thus preventing to a great extent the penetration of the medicament into the insertion channel of the needle.
A volume adapter (410) can advantageously be used to predetermine the injection stroke (H2) and thus the quantity of a medicament that is administered during the course of the injection stroke (H2).
Owner:BAYER INTELLECTUAL PROPERTY GMBH

Tissue lockable connecting structures

Percutaneous skin access devices include a plurality of locked connecting units mounted to the exterior surface of an implantable medical object which, in position, is configured to penetrate the skin of a subject. The locked connecting units may be mounted directly onto the desired surface of the exterior of the device or may be held on a substrate sheet, which is mounted to the exterior surface of the device. In position, the locked connecting units engage with soft tissue which can include the skin to form a bio-junction layer which includes mechanical and bio-sealing connection between the device body and the soft tissue. The configuration at the bio-junction layer secures the medical object in location in the subject even for long-term indwelling applications in a manner, which inhibits soft tissue infection.
The locked connecting units may be rigid or semi-rigid for longer-term indwelling applications, and semi-rigid and/or resilient for shorter term indwelling applications. The locked connecting units may take on the form of rings, hooks, or loops having aperture or gap width/length sizes of from about 0.2–4 mm. The rings, loops, or hooks may connect with any soft tissue including skin as well subcutaneous tissue. The rings, hooks, or loops may be released from the skin/tissue without requiring surgical cutting procedures.
The locked connecting units may be configured as a semi-rigid mesh collar arranged about the primary body providing access to the subject such that it resides in the subject and engages with the skin (epidermal/dermal layer). The mesh collar can be described as a particular type of ring or loop structure as the mesh defines the gap provided in individual loop configurations. The mesh collar may be used alone, or in combination with the loops, rings, or hooks. A skin stop collar having increased rigidity may be disposed under the mesh collar.
Owner:EAST CAROLINA UNIVERISTY

Compositions and methods for the treatment of cancer

InactiveUS20020128228A1Reducing and avoiding adverse effectImprove toleranceBiocideAnimal repellantsIntestinal structureCancer prevention
This invention relates to compositions comprising temozolomide and thalidomide which can be used in the treatment or prevention of cancer, in particular malignant melanoma, cancer of the skin, subcutaneous tissue, lymph nodes, brain, lung, liver, bone, intestine, colon, heart, pancreas, adrenals, kidney, prostate, breast, colorectal, or a combination thereof. A particular composition comprises temozolomide, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, and thalidomide, or a pharmaceutically acceptable salt, solvate, or clathrate thereof. The invention also relates to methods of treating or preventing cancer, in particular malignant melanoma, cancer of the skin, subcutaneous tissue, lymph nodes, brain, lung, liver, bone, intestine, colon, heart, pancreas, adrenals, kidney, prostate, breast, colorectal, or a combination thereof, which comprise the administration of temozolomide and thalidomide and another anti-cancer drug to a patient in need of such treatment or prevention. The invention further relates to methods of reducing or avoiding adverse side effects associated with the administration of cancer chemotherapy or radiation therapy which comprise the administration of temozolomide and thalidomide to a patient in need of such reduction or avoidance.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT

Methods and apparatus for transesophageal microaccess surgery

The current invention describes methods of transesophageal access to the neck and thorax to perform surgical interventions on structures outside the esophagus in both the cervical and the thoracic cavity. It describes a liner device made of a complete or partial tubular structure, or a flat plate, the liner having means to facilitate creation of a side opening, which may include a valve. The liner with its side opening form a port structure inside the esophageal lumen. The port structure allows elongated surgical devices to pass through a perforation across the full thickness of the esophageal wall to outside location, in a controlled way. The elongated surgical devices can be diagnostic scopes, therapeutic scopes, manual elongated surgical devices, robotic arms or the like. After being deployed outside the esophagus, the surgical devices can access structures outside the esophagus, in the neck and thorax in 360 degrees of freedom around the esophageal circumference. These structures can be bony, cartilaginous, spinal, vascular, soft tissue, deep tissues, lymph nodal, cardiac, pulmonary, tracheal, nervous, muscular or diaphragmatic, skin and subcutaneous tissues of the neck, skin and subcutaneous tissues of the anterior chest wall, skin and subcutaneous tissues of the skin of the back, and skin and layers of the breast.
Owner:MICROACCESS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products